Incannex Healthcare

Incannex Healthcare rallied strongly during regular trading, reaching $3.94 as of 10:05 ET, up 6.2% from the prior close of $3.71, driven by the U.S. Patent and Trademark Office granting a patent for IHL-42X to treat obstructive sleep apnea, coupled with a prior A$6.0M R&D tax refund and expectations of over A$11.1M in non-dilutive funding. The stock formed a single-session upward trend from the open of $3.71 to an intraday high of $3.94, with total volume of 14,333 shares. Despite ongoing losses—a net loss of $3.883M in Q3 2026, narrowing 2.14% YoY—the stock has rebounded sharply from its YTD low of $0.155, posting a YTD gain of 910.26%. Currently at $3.94, it trades above both its 20-day MA of $3.538 and 60-day MA of $3.717, though it remains 39.04% below the 52-week high of $6.463.